{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T16:45:34Z","timestamp":1760287534697,"version":"build-2065373602"},"reference-count":6,"publisher":"Wiley","issue":"20","license":[{"start":{"date-parts":[[2024,9,26]],"date-time":"2024-09-26T00:00:00Z","timestamp":1727308800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["acsjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2024,10,15]]},"abstract":"<jats:p>This news section offers <jats:italic>Cancer<\/jats:italic> readers timely information on events, public policy analysis, topical issues, and personalities. This issue features Dr Eileen M. O\u2019Reilly, whose research has resulted in the first new therapy in more than a decade for treatment\u2010na\u00efve metastatic pancreatic cancer. In addition, androgen receptor signaling inhibitors have been linked to increased risk of cardiovascular adverse events in prostate cancer, and radiation alone has excellent outcomes for localized recurrences of endometrial cancer.<\/jats:p>","DOI":"10.1002\/cncr.35554","type":"journal-article","created":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T00:57:03Z","timestamp":1727398623000},"page":"3398-3398","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["First person profile: Eileen M. O\u2019Reilly, MD"],"prefix":"10.1002","volume":"130","author":[{"given":"Mary Beth","family":"Nierengarten","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2024,9,26]]},"reference":[{"key":"e_1_2_3_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)01366-1"},{"key":"e_1_2_3_3_1","unstructured":"FDA approves irinotecan liposome for first\u2010line treatment of metastatic pancreatic adenocarcinoma. Press release. US Food and Drug Administration. February 13 2024.https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-irinotecan-liposome-first-line-treatment-metastatic-pancreatic-adenocarcinoma"},{"key":"e_1_2_3_4_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.02931"},{"key":"e_1_2_3_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1903387"},{"key":"e_1_2_3_6_1","unstructured":"FDA approves olaparib for gBRCAm metastatic pancreatic adenocarcinoma. Press release. US Food and Drug Administration. December 27 2019.https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-olaparib-gbrcam-metastatic-pancreatic-adenocarcinoma#:~:text=On%20December%2027%2C%202019%2C%20the an%20FDA%2Dapproved%20test%2C%20whose"},{"key":"e_1_2_3_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02760-3"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.35554","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T16:05:51Z","timestamp":1760285151000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.35554"}},"subtitle":["Dr O\u2019Reilly\u2019s research has resulted in the first new therapy in more than a decade for treatment\u2010na\u00efve metastatic pancreatic cancer."],"short-title":[],"issued":{"date-parts":[[2024,9,26]]},"references-count":6,"journal-issue":{"issue":"20","published-print":{"date-parts":[[2024,10,15]]}},"alternative-id":["10.1002\/cncr.35554"],"URL":"https:\/\/doi.org\/10.1002\/cncr.35554","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"type":"print","value":"0008-543X"},{"type":"electronic","value":"1097-0142"}],"subject":[],"published":{"date-parts":[[2024,9,26]]},"assertion":[{"value":"2024-09-26","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}